Last Updated on October 2, 2024 by The Health Master
Glenmark Pharma has received final approval by the United States Food & Drug Administration (USFDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza Tablets, 2.5 mg and 5 mg, of AstraZeneca AB.
Glenmark’s Saxagliptin Tablets, 2.5 mg and 5 mg, will be distributed in the US by Glenmark Pharma, USA.
According to IQVIA sales data for the 12‐month period ending June 2023, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately $100.7 million.
Glenmark’s current portfolio consists of 184 products authorised for distribution in the US marketplace and 49 ANDAs pending approval with the USFDA.
USFDA gives approval for Saxagliptin Tablets
USFDA gives marketing approval for this Birth Control Pill
USFDA gives nod to market this cancer treatment generic injection
USFDA gives approval for Plerixafor injection
USFDA gives approval this drug as first treatment for a type of skin infection
Govt to implement GMP for Pharma Companies to enhance quality and global acceptance
DCGI asks manufacturers: Not to submit same batch of cough syrup to multiple Laboratories
NIPER: A Comprehensive Guide to NIPER Institutes in India
3D printed Medical Device developed for rapid diagnosis of UTI
Physical and Chemical parameters of Excipient affect its functionality and Drug Quality: Experts
Illegal Drugs worth more than Rs. 50 Lakh seized from warehouses in Agra
Drug recall: Sun Pharma, Alembic recall these drugs due to this reason
Latest on Indian Pharmacopoeia Commission (IPC)
Lok Sabha passes The Jan Vishwas Bill to Amend Drugs and Cosmetics Act
NPPA fixed ceiling prices of 915 scheduled formulations till mid July
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
